Psychiatry and Neurology, Neurology · Clearwater, FL
NPI
1447249115
Since 2005
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
3190 N McMullen Booth Rd Ste 200
Clearwater, FL, 33761
Phone (813) 855-2900
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.2M
51,905 services
Medicare patients, 2024
156
Average age 68
Drug cost, 2024
$2.9M
2,619 prescriptions
Company payments, 2025
$116K
From 38 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mark C Cascione was code J2350 (injection, ocrelizumab, 1 mg), 39,600 times for 38 patients. In total Mark C Cascione billed 51,905 services in 22 codes, and Medicare paid $2.2M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-08-13.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J2350 Injection, ocrelizumab, 1 mg | Office | 39,600 | 38 | $46.09 | $1.8M |
| 99215 Office E&M - Established | Office | 208 | 128 | $123.51 | $26K |
| 96413 Chemotherapy Administration | Office | 123 | 51 | $92.90 | $11K |
| 96415 Chemotherapy Administration | Office | 97 | 43 | $20.34 | $1,973 |
| 96375 Injection Administration | Office | 60 | 37 | $11.60 | $696 |
| 99214 Office E&M - Established | Office | 54 | 43 | $80.51 | $4,348 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 27 | 25 | $12.88 | $348 |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 18 | 18 | $0.23 | $4.16 |
| J2930 Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 15 | 14 | $4.61 | $69.15 |
By year: 2022 $1.9M for 47,195 services; 2023 $2.1M for 50,927 services; 2024 $2.2M for 51,905 services.
Medicare prescription drug claims, 2024
In 2024, the drug Mark C Cascione prescribed most often to Medicare patients was Baclofen, with 205 prescriptions and refills. In total Mark C Cascione wrote 2,619 Medicare prescriptions that cost $2.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Baclofen Generic | 205 | 395 | 42 | $4,221 |
| Gabapentin Generic | 160 | 340 | 40 | $3,142 |
| Alprazolam Generic | 115 | 129 | 21 | $723 |
| Dalfampridine Er Dalfampridine | 102 | 164 | 17 | $103K |
| Tizanidine Hcl Generic | 101 | 191 | 23 | $1,528 |
| Carbamazepine Generic | 84 | 169 | 20 | $4,332 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 64 | 70 | 13 | $1,560 |
| Clonazepam Generic | 61 | 81 | 11 | $412 |
| Diazepam Generic | 58 | 106 | 18 | $701 |
| Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine | 51 | 53 | Under 11 | $2,623 |
| Duloxetine Hcl Generic | 50 | 98 | 11 | $811 |
| Sertraline Hcl Generic | 50 | 133 | 13 | $167 |
| Zeposia Ozanimod Hydrochloride | 49 | 61 | Under 11 | $521K |
| Zolpidem Tartrate Generic | 49 | 55 | Under 11 | $455 |
| Pregabalin Generic | 48 | 78 | Under 11 | $1,013 |
Brand drugs: - claims; generic drugs: 2,273 claims; opioid claims: 138.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mark C Cascione $116K ($116K in general payments such as food, travel and fees) from 38 companies. The largest payer was Vanda Pharmaceuticals Inc. with $33K.
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. VNDA | 36 | $33K |
| TG Therapeutics, Inc. TGTX | 46 | $30K |
| E.R. Squibb & Sons, L.L.C. BMY | 12 | $18K |
| Biogen, Inc. BIIB | 37 | $17K |
| Genentech USA, Inc. ROG.SW | 17 | $7,962 |
| Novartis Pharmaceuticals Corporation NVS | 27 | $2,116 |
| Celgene Corporation BMY | 19 | $1,698 |
| Abbvie Inc. ABBV | 28 | $603 |
| Genzyme Corporation SNY | 14 | $563 |
| Lundbeck LLC | 14 | $360 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.